# AstraZeneca’s Brilinta met primary endpoint in Phase III trial

- Link: https://www.directorstalkinterviews.com/astrazenecas-brilinta-met-primary-endpoint-in-phase-iii-trial/412804028
- Published: 2020-01-27T07:28:02+00:00
- Author: Amilia Stone

High-level results from the Phase III THALES trial showed **AstraZeneca** ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Brilinta_ (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days,
reached a statistically significant and clinically meaningful reduction in the risk
of the primary composite endpoint of stroke and death, compared to aspirin alone.

THALES was conducted in over 11,000 patients who had a minor acute ischaemic stroke
or high-risk transient ischaemic attack (TIA) in the 24 hours prior to treatment
initiation. The preliminary safety findings in the THALES trial were consistent 
with the known profile of _Brilinta_, with an increased bleeding rate in the treatment
arm.

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said:** “Results
> of the Phase III THALES trial showed _Brilinta,_ in combination with aspirin, 
> improved outcomes in patients who had experienced a minor acute ischaemic stroke
> or high-risk transient ischaemic attack. We look forward to sharing the detailed
> results with health authorities.”

> **Dr. Clay Johnston, lead investigator for the THALES trial and Dean of the Dell
> Medical School at The University of Texas at Austin, US, said: **_“_The risk of
> having a subsequent stroke is highest in the first few days and weeks after a 
> minor acute ischaemic stroke or high-risk transient ischaemic attack. While an
> expected increase in bleeding was observed, the findings from THALES showed that
> _Brilinta,_ in combination with aspirin, reduced the risk of potentially devastating
> events in this crucial time.”

The full THALES trial results will be presented at a forthcoming medical meeting.

_Brilinta_ is approved in more than 110 countries for the treatment of acute coronary
syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular(
CV) events among high-risk patients who have experienced a heart attack.

**Stroke**

Stroke is the second leading cause of death worldwide, with 6.2 million stroke-related
deaths in 2017, from which 2.7 million were due to ischaemic stroke.^(1) Patients
who experience an acute ischaemic stroke or TIA are at high risk of developing subsequent
ischaemic events, with particularly high risk within 30 days after the initial event
and the highest risk period being the first 24 hours after the initial event.^(2)

**THALES**

THALES is an AstraZeneca-sponsored, randomised, placebo-controlled, double-blinded,
international, multicentre, event-driven trial involving more than 11,000 patients
to test the hypothesis whether _Brilinta_ and aspirin is superior to aspirin alone
in preventing the composite of stroke and death in patients with minor acute ischaemic
stroke or high-risk TIA. Patients were randomised within 24 hours of onset of acute
ischaemic stroke or high-risk TIA symptoms and followed-up for 30 days of treatment.
Trial treatments were _Brilinta_ 180mg loading dose on day 1 as soon as possible
after randomisation, followed by 90mg twice daily on days 2-30, or matching placebo.
All patients received open-label aspirin 300-325mg on day 1, followed by 75-100mg
once daily on days 2-30. The primary efficacy outcome was the time to the composite
endpoint of stroke and death at 30 days. The primary safety outcome is time to first
severe bleeding event according to the Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition. Patients
were followed for an additional 30 days on standard of care.

**Brilinta**

_Brilinta_ is an oral, reversible, direct-acting P2Y12 receptor antagonist that 
works by inhibiting platelet activation. _Brilinta_, together with aspirin, has 
been shown to significantly reduce the risk of major adverse CV events (myocardial
infarction, stroke or CV death), in patients with ACS or a history of myocardial
infarction (MI).

_Brilinta_, co-administered with aspirin, is indicated for the prevention of atherothrombotic
events in adult patients with ACS, or for patients with a history of MI and a high
risk of developing an atherothrombotic event.

**AstraZeneca in CVRM**

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s 
three therapy areas and is a key growth driver for the Company. By following the
science to understand more clearly the underlying links between the heart, kidneys
and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs
and improve outcomes by slowing disease progression, reducing risks and tackling
comorbidities. The Company’s ambition is to modify or halt the natural course of
CVRM diseases and potentially regenerate organs and restore function, by continuing
to deliver transformative science that improves treatment practices and cardiovascular
health for millions of patients worldwide.

Share on:
